Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Capital Expenditures: 2023-2025

Historic Capital Expenditures for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $962,000.

  • Tonix Pharmaceuticals Holding's Capital Expenditures rose 10588.89% to $962,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 36.74%. This contributed to the annual value of $120,000 for FY2024, which is 98.48% down from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Capital Expenditures is $962,000, which was up 82.54% from $527,000 recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Capital Expenditures high stood at $3.8 million for Q1 2023, and its period low was $3,000 during Q4 2024.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Capital Expenditures had a median value of $482,500 in 2023 and averaged $951,000.
  • In the last 5 years, Tonix Pharmaceuticals Holding's Capital Expenditures crashed by 99.50% in 2024 and then spiked by 10,588.89% in 2025.
  • Tonix Pharmaceuticals Holding's Capital Expenditures (Quarterly) stood at $438,000 in 2023, then crashed by 99.32% to $3,000 in 2024, then spiked by 10,588.89% to $962,000 in 2025.
  • Its last three reported values are $962,000 in Q3 2025, $527,000 for Q2 2025, and $6,000 during Q1 2025.